Home > Boards > US Listed > Biotechs >

DTIL (DTIL)

DTIL RSS Feed
Add DTIL Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/18/2022 9:35:32 PM - Followers: 16 - Board type: Free - Posts Today: 0

DTIL
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
DTIL News: Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection 05/18/2022 03:00:00 AM
DTIL News: Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting 05/16/2022 03:00:00 AM
DTIL News: Statement of Changes in Beneficial Ownership (4) 05/12/2022 03:17:49 AM
DTIL News: Statement of Changes in Beneficial Ownership (4) 05/12/2022 03:16:33 AM
DTIL News: Statement of Changes in Beneficial Ownership (4) 05/12/2022 03:15:42 AM
PostSubject
#131   Knocking out genes that express IL-1R1, .... in NY1972 05/18/22 09:35:32 PM
#130   I do think CAR-T's will have a role jondoeuk 05/18/22 01:24:23 PM
#129   Sounds like the second for up to five jondoeuk 05/18/22 01:18:04 PM
#128   How about inserting MMR gene into MSI cancers NY1972 05/16/22 06:04:53 PM
#127   If DTIL can unsteath cancer cells before treating NY1972 05/16/22 10:51:26 AM
#126   ADXS called that HOT. It turned out to NY1972 05/16/22 10:20:42 AM
#125   It is 'personalised' in a sense. ADAP will jondoeuk 05/15/22 09:13:06 PM
#124   Is 'personalized allogeneic' oxymoron? NY1972 05/15/22 08:49:45 PM
#123   I do think they should focus on their jondoeuk 05/15/22 01:16:38 PM
#122   I agree. RHHBY's Genentech signed a deal with jondoeuk 05/15/22 01:03:07 PM
#121   Cell therapy will be the backbone of therapies NY1972 05/14/22 09:26:23 PM
#120   NVS should buy DTIL with their stockpile of peanuts. NY1972 05/12/22 04:13:13 PM
#119   New YTB323 data https://library.ehaweb.org/eha/2022/eha2022-congress/357076/mich jondoeuk 05/12/22 02:37:39 PM
#118   NVS claimed to deliver 10-50 fold few CART NY1972 05/10/22 08:13:33 PM
#117   Is NVS picking CD39-CD69- t cells? jondoeuk 05/10/22 06:50:46 PM
#116   Is NVS picking CD39-CD69- t cells? Which alloc NY1972 05/10/22 11:36:06 AM
#115   ARCUS is safe relatively speaking. NY1972 05/09/22 11:28:48 AM
#114   Hi NY1972, ARCUS is superior in soooo MI Dendream 05/08/22 11:45:02 PM
#113   Ticking time bomb? monitoring patients undergoing CRISPR-Cas9-based editing NY1972 05/07/22 07:08:39 PM
#112   Too many biotechs were fat pigs destined for NY1972 05/06/22 06:39:51 PM
#111   T-charge must be a magical hotel for the NY1972 05/06/22 06:31:48 PM
#110   Nothing I could fine. Q1 financials are on Monday. jondoeuk 05/06/22 04:20:24 PM
#109   It seems that instead of the current activation jondoeuk 05/06/22 04:18:06 PM
#108   No bad news after 12% sell down? NY1972 05/05/22 10:29:46 PM
#107   If LD conditioning is part of the treatment, NY1972 05/03/22 10:49:42 PM
#106   No, but it is used. Either fludarabine (30 jondoeuk 05/03/22 05:12:49 PM
#105   No LD mentioned in YTB323 P1 protocol NY1972 05/03/22 05:06:59 PM
#104   YTB323 (anti-CD19) is being tested in patients with jondoeuk 05/03/22 04:16:35 PM
#103   PBCAR0191 with eLD will be targeting AUTO CART NY1972 05/02/22 09:20:07 PM
#102   CART T as 1st line treatment without LD? NY1972 05/02/22 09:05:31 PM
#101   Based on the data so far, PBCAR0191 with jondoeuk 05/02/22 08:49:38 PM
#100   Clinical data https://www.globenewswire.com/news-release/2021/12/13/2351117/0/en jondoeuk 05/02/22 08:35:13 PM
#99   NVS CART T needs a charge soon. Selling NY1972 05/02/22 02:20:44 PM
#98   If CMO can deliver 80% ORR with 50% NY1972 05/02/22 01:31:07 PM
#97   Yes, but I think they need to be jondoeuk 05/02/22 12:16:39 PM
#96   VX-880 is an allo (stem cell-derived), insulin-producing islet jondoeuk 05/02/22 12:12:57 PM
#95   No immunosuppressive regimen needed for in vivo edit NY1972 05/02/22 11:20:00 AM
#94   I will be interested to hear how many NY1972 05/01/22 10:18:14 PM
#93   No, but I doubt the market will view jondoeuk 05/01/22 08:27:29 PM
#92   FT596, not working for DLBCL NY1972 04/30/22 11:14:29 PM
#91   FT516-101: Interim Phase 1 Clinical Data in R/R NY1972 04/30/22 10:53:05 PM
#90   Inserting beta-2 microglobulin gene into tumor cells with NY1972 04/30/22 02:45:40 PM
#89   DTIL mgt. should cut burn to allow in NY1972 04/29/22 10:26:19 PM
#88   I guess you are expecting bad news. NY1972 04/29/22 07:25:03 PM
#87   Well, I won't be buying, as there is jondoeuk 04/29/22 07:11:38 PM
#86   PBCAR0191 in Patients With r/r NHL and r/r NY1972 04/28/22 03:27:56 PM
#85   DTIL is a bargain? NY1972 04/28/22 10:40:56 AM
#84   Another https://www.fiercebiotech.com/research/designing-better-car-t-cell-thera jondoeuk 04/02/22 08:24:47 PM
#83   I have found some the other knockouts, which jondoeuk 03/30/22 06:30:07 PM
#82   Well, if it has been designed to overcome jondoeuk 03/30/22 06:24:13 PM
PostSubject
Consent Preferences